Evidence synthesis for decision making 1: Introduction

Medical Decision Making

Volumn 33, Issue 5, 2013, Pages 597-606

  Dias, Sofia ^a   Welton, Nicky J ^b   Sutton, Alex J ^b   Ades, A E ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b NONE

Author keywords

Bayesian meta analysis; cost effectiveness analysis; systematic reviews

Indexed keywords

DECISION MAKING; EVIDENCE BASED MEDICINE; ARTICLE; BAYESIAN META-ANALYSIS; COST-EFFECTIVENESS ANALYSIS; SYSTEMATIC REVIEW (TOPIC);

DECISION MAKING; EVIDENCE-BASED MEDICINE;

BAYESIAN META-ANALYSIS; COST-EFFECTIVENESS ANALYSIS; SYSTEMATIC REVIEWS;

EID: 84879750973     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X13487604     Document Type: Article

References (41)

1. National Institute for Health and Clinical Excellence. Guide to the single technology appraisal (STA) process. September2009. Available from: URL: http://www.nice.org.uk/media/42D/B3/STAGuideLrFinal.pdf
2. National Institute for Health and Clinical Excellence. Guide to the multiple technology appraisal process (reference N2022). September2009. Available from: URL: http://www.nice.org.uk/media/42D/8C/MTAGuideLRFINAL.pdf
3. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal (updated June 2008). Available from: URL: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf
4. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal, third edition: draft for consultation. 2012. Available from: URL: http://www.nice.org.uk/media/CB1/43/ GuideToMethodsOfTechnologyAppraisal2012.pdf
5. London: National Institute for Health and Clinical Excellence ; 2009:
6. National Institute for Health and Clinical Excellence. The Guidelines Manual. London: National Institute of Health and Clinical Excellence; 2012. Available from: URL http://publications.nice.org.uk/the-guidelines-manual-pmg6
7. Sutton A, Cooper N, Goodacre A, Stevenson M. Integration of meta-analysis and economic decision modeling for evaluating diagnostic tests. Med Decis Making. 2008 ; 28 (5). 650-67
8. Ades AE, Sutton AJ. Multiparameter evidence synthesis in epidemiology and medical decision making: current approaches. J R Stat Soc Ser A Stat Soc. 2006 ; 169 (1). 5-35
9. van Valkenhoef G, Tervonen T, Zhao J, de Brock B, Hillege H, Postmus D. Multi-criteria benefit-risk assessment using network meta-analysis. J Clin Epidemiol. 2012 ; 65: 394-403
10. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalised linear modeling framework for pairwise and network meta-analysis of randomised controlled trials. Med Decis Making. 2013 ; 33 (5). 607-617
11. Dias S, Sutton AJ, Welton NJ, Ades AE. Evidence synthesis for decision making 3: heterogeneity-subgroups, meta-regression, bias and bias-adjustment. Med Decis Making. 2013 ; 33 (5). 618-640
12. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomised controlled trials. Med Decis Making. 2013 ; 33 (5). 641-656
13. Lunn D, Spiegelhalter D, Thomas A, Best N. The BUGS project: evolution, critique and future directions. Stat Med. 2009 ; 28: 3049-67
14. SpiegelhalterDThomasABestNLunnD. WinBUGS user manual version 1.4 January 2003. Upgraded to version 1.4.32007. Available from: URL: http://www.mrc-bsu. cam.ac.uk/bugs
15. Congdon P Bayesian Statistical Modeling. Chichester, UK: Wiley ; 2001:
16. Welton NJ, Sutton AJ, Cooper NJ, Abrams KR, Ades AE Evidence Synthesis for Decision Making in Healthcare. New York: Wiley ; 2012:
17. Spiegelhalter DJ, Abrams KR, Myles J Bayesian Approaches to Clinical Trials and Health-Care Evaluation. New York: Wiley ; 2004:
18. Dias S, Welton NJ, Sutton AJ, Ades AE. Evidence synthesis for decision making 5: the baseline natural history model. Med Decis Making. 2013 ; 33 (5). 657-670
19. Dias S, Sutton AJ, Welton NJ, Ades AE. Evidence synthesis for decision making 6: embedding evidence synthesis in probabilistic cost-effectiveness analysis. Med Decis Making. 2013 ; 33 (5). 671-678
20. Ades AE, Caldwell DM, Reken S, Welton NJ, Sutton AJ, Dias S. Evidence synthesis for decision making 7: a reviewer's checklist. Med Decis Making. 2013 ; 33 (5). 679-691
21. National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. February2008. Available from: URL: http://www.nice.org.uk/media/C18/30/SVJ2PUBLICATION2008.pdf
22. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002 ; 21: 2313-24
23. Batagelj V, Mrvar A. Pajek - program for large network analysis. Connections. 1998 ; 21 (2). 47-57
24. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2010. Available from: URL: http://www.R-project.org
25. SalantiG. Multiple-treatments meta-analysis of a network of interventions. 2011. Available from: URL: http://www.mtm.uoi.gr/
26. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010 ; 29: 932-44
27. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009 ; 373: 746-58
28. Ades AE, Mavranezouli I, Dias S, Welton NJ, Whittington C, Kendall T. Network meta-analysis with competing risk outcomes. Value Health. 2010 ; 13 (8). 976-83
29. Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011 ; 64: 163-71
30. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004 ; 23: 1351-75
31. Carlin JB. Meta-analysis for 2 x 2 tables: a Bayesian approach. Stat Med. 1992 ; 11 (2). 141-58
32. Hooper L, Summerbell CD, Higgins JPT, et al. Reduced or modified dietary fat for preventing cardiovascular disease. Cochrane Database Syst Rev. 2000 ; ( 2 ):
33. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007 ; 369 (9557). 201-7
34. Franchini A, Dias S, Ades AE, Jansen J, Welton N. Accounting for correlation in mixed treatment comparisons with multi-arm trials. Research Synthesis Methods. 2012 ; 3: 142-60
35. Woolacott N, Hawkins NS, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess. 2006 ; 10 (46). 1-233
36. Sutton AJ Leicester, UK: University of Leicester ; 2002:
37. National Institute for Health and Clinical Excellence. Certolizumab pegol for the treatment of rheumatoid arthritis. 2010. Report no. TA186. Available from: URL: http://guidance.nice.org.uk/TA186
38. Hasselblad V. Meta-analysis of multi-treatment studies. Med Decis Making. 1998 ; 18: 37-43
39. Lu G, Ades A. Assessing evidence consistency in mixed treatment comparisons. J Am Stat Assoc. 2006 ; 101: 447-59
40. Boland A, Dundar Y, Bagust A, et al. Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation. Health Technol Assess. 2003 ; 7 (15). 1-136
41. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003 ; 361: 13-20